



Prof. Brigitte DRENO


Professor of Dermatology, Chairman of the Department of Dermatology, Nantes Hospital, Director of the Cancer Research Center of Nantes University Hospital, Director of the Biotherapy Clinical Investigation Center (Inserm 0503) and of the GMP Unit of Cell and Gene Therapy brigitte.dreno@wanadoo.fr

Prof. Céleste LEBBE

Professor of Dermatology, Head of the Skin Cancer Unit in the Department of Dermatology, Saint-Louis Hospital, Paris, Coordination of clinical research on melanoma in Saint Louis Hospital, Paris, Coordination of a platform of melanoma experimental models in Inserm U976


OVERVIEW

partners



Aims of the RIC-Mel network are to promote translational research, to optimize the achievements of clinical trials and to support basic research.

Aim of the RIC-Mel database is to give a permanently updated mapping of melanoma treated in France with the key information needed for any research projects.



Positioning

The RIC-Mel database is linked to the clinico-biologico-

radiological database MELBASE dedicated to metastatic melanoma stage IV and unresectable stage III (settingup by Saint-Louis hospital, Paris. Coordinated by Prof. C. LEBBE and Prof. B. DRENO)

> To date, the RIC-Mel cohort is the only one in France to take

the census of the active file of melanoma patients

> Currently, four partnerships with pharmaceutical companies are on-going

> The RIC-Mel database aims to be opened to academic and new industrial patnerships

COHORT INNOVATION DAY

LEADERSHIP

RIC-Mel's leadership team brings together renown clinicians and researchers who have been committed in the field of melanoma since 25 years.

Prof. Brigitte DRENO, Dermatology – Coordinator Chairman of the Department of Dermatology at Nantes hospital

Research areas with significant contribution:

> Skin cancers: Melanoma (immunotherapy), Basal cell carcinoma, Cutaneous lymphoma

> Dermatology: Actinic keratosis, Acne and related disorders, Dermocosmetics

Expertise:

> Expert for national and European Agencies: European Medicines Agency (EMEA), French National Agency for Medicines and Health Products Safety (ANSM), French National Cancer Institute (INCa), Evaluation Agency for Research and Higher education (AERES)

Memberships:

> National: French Society of Dermatology (SFD), French College of Teachers in Dermatology

International: European Society of Dermatology (EADV), European Society for Dermatological Research (ESDR), European Academy of Dermatological Oncology (EADO), International Society for Cutaneous Lymphoma (ISCL), American Academy of Dermatology (AAD), Foreign member of the Canadian Society of Dermatology, Member of the Skin Cancer Foundation, Treasurer of the International League of National Dermatology (ILDS)

International Editorial Board:

> 2015: Journal of the European Academy of Dermatology and Venereology

> 2009: International Journal of Clinical Dermatology and International Immunotherapy

> 2006: European Journal of Cancer Prevention

Publications:

> 556 publications; h-index: 42

Coordination of 2 others networks in melanoma:

- > Regional network: BioRderm (since 2007)
- > Local network: CRESIP (since 2011)

Prof. Célèste LEBBE, Dermatology – Coordinator

Head of the Skin Cancer Unit in the Department of Dermatology at Saint-Louis Hospital (Paris)

Coordination of clinical research on melanoma in Saint-Louis Hospital, Paris

Coordination of a platform of melanoma experimental models in Inserm unit U976

Board member

- > French Society of Dermatology (SFD)
- > European Society for Dermatological Research (ESDR)
- > European Academy of Dermatological Oncology (EADO) (on board)
- > EORTC
- > SCOPE

Coordination of 1 other network in melanoma:

> National network: MELBASE, dedicated to metastatic melanoma stage IV and unresectable stage III

SCIENTIFIC NETWORK & MANAGEMENT

The RIC-Mel constitutes the French national database of the Skin Cancerology Group (GCC)

The RIC-Mel database is **interconnected with MELBASE** (clinico-biologico-radiological database dedicated to metastatic melanoma stage IV and unresectable stage III, setting-up by Saint-Louis Hospital, Paris. Coordinated by Prof. C. LEBBE and Prof. B. DRENO)

The RIC-Mel governance is organized on the basis of two instances:

Steering Committee: deciding authority

- > Prof. Brigitte DRENO, CHU de Nantes
- > Pr Célèste LEBBE, Saint Louis Hospital (AP-HP)

> Dr Didier CUPISSOL, CLCC Val d'Aurelle Paul Lamarque, Montpellier

- > Dr Bernard GUILLOT, CHRU de Montpellier
- > Dr Lionel LARUE, CNRS UMR 3347 / Inserm U1021
- > Prof. Marie-Thérèse LECCIA, CHU de Grenoble
- > Dr Florence VRIGNAUD, CIC Biothérapies, CHU de Nantes

- Scientific Council: evaluation of scientific projects
- > Dr Florence GRANEL-BROCARD, CHU de Nancy
- > Dr Idalie JENNESSEAUX, Groupement Hospitalier du Havre
- > Prof. Catherine LOK, CHU d'Amiens
- > Dr Caroline ROBERT, Institut de Cancérologie Gustave Roussy
- > **Prof. Philippe MODIANO**, Groupement des Hôpitaux de l'Institut Catholique de Lille
- > Prof. Florent GRANGE, CHU de Reims
- > Dr Thomas JOUARY, CH de Pau
- > Dr Nicolas MEYER, CHU de Toulouse
- > Prof. Luc THOMAS, Hospices Civils de Lyon

PROJECT DESCRIPTION

SCIENTIFIC OBJECTIVES
 Main objectives To promote phase I/II clinical trials in the field of melanoma in France To give a permanently updated mapping of melanoma treated in France with the key information needed for any research projects
 Secondary objectives To promote translational research, to optimize the achievements of clinical trials and to support basic research To federate clinical centers of dermatology and oncology as well as network related to me-lanoma around a common database To be a privileged interlocutor for industrial partners
 Ultimate goal To be an interlocutor of quality for national and European authorities as well as industrial partners in order to ensure an international legibility to any French research on melanoma

INNOVATIVE SCIENTIFIC FEATURES -

RIC-Mel is unique as a national database regarding all melanoma patients

RIC-Mel is recognized and validated by the French Society of Dermatology (SFD), the Skin Cancerology Group (GCC) and the health authorities as the single point of entry when requesting the access of data upon melanoma patients for translational/clinical research projects

METHODOLOGY QUALITY -

The updated **database can be accessible by RIC-Mel at any given moment** and each center has an exclusive access for its own data


All patients included in the database agreed to participate and data are treated confidentially

The database has been approved by French Health Authorities, both ethically (CCTIRS) and confidentially for data (CNIL)

Data related to biological samples are collected for patients who have signed a consent form specific to each participating center

Quality management system based on ISO 9001 standards (in progress)

DESIGN, METHODOLOGY & TIMELINE



Recruitment objectives:	Around 2,000 enrolled expected patients per year	
Sites:	48 participating centers: 41 General Hospitals, 6 centres de lutte contre le cancer (Cancer Centers) and 1 Hôpital d'Instruction des Armées (Army Hospital)	
Inclusion criteria:	All melanoma patients followed in participating centers and agreed to participated Patients must be alive at the time of inclusion in the database	

INCLUSION COLLECTION Database:

Part I (mandatory): Identity, Primary tumor, AJCC stage, Mutations, Antigens, Treatments

Part II (optional): Family history of melanoma, Metastases, HLA type, Sample collection, Doses, Global response and Adverse events (grade 3 & 4) for Curative and Investigational treatments

FOLLOW-UP: ACCORDING TO DISEASE PROGRESSION

RIC-MEL

Database:

Part I (mandatory): AJCC Stage evolution, New treatment lines, Death...

Part II (optional): Metastases, Sample collection, Doses, Global response and Adverse events (grade 3 & 4) for Curative and Investigational treatments

DATABASE & BIOBANK CONTENTS

DATABASE

PART I - Mandatory									
Identity	Initials		Birth date				Gender		
	Date of surgery	Type of melanoma	Breslow	М	litotic index	Ulceration	Regression		
Primary tumor		lymph node rgery		Date		Results			
	Lymph node removal Number of invaded lymph node		Extracapsular extension						
AJCC Stage at inclusion and evolution	Date of diagnosis		Details		For stage III only : if inoperable or not				
Mutations	Туре		Pres	sence	Date	Comn	nents		
Antigens	Туре		Presence		Date	Comments			
Treatment	Т	уре	Na	ame	Nature (adjuvant/curative)	Dates			
Death		Yes/No			Date				

PART II - Optional								
Family history	Genetic investigation							
Metastases	Type D		Date of diagnostic		Presence			
HLA type			А	В				
Sample collection	Type (skin, blood, metastases)		Storage condition		Date			
		Cor	nment	Storage location				
Curative and investigational treatments		D	osage	Response				
Adverse events (grade 3 and 4)	Туре	Gra	ade	Action on treatment	Other action	Outcome		

ACCESS MODALITIES TO ANY REQUEST FOR DATA ANALYSIS

Submission of a scientific project to the Scientific Council of the RIC-Mel network

> containing the rational and the objective(s) of the study as well as a description of the data analysis

In case of the project is approved by the Scientific Council, a collaboration agreement is established with the Nantes Hospital, in respect of its coordinating center of the RIC-Mel network status

Extraction and results of the data analysis from the national active list of patients with melanoma are transmitted *via* as aggregated data file

COHORT INNOVATION DAY

RESEARCH COLLABORATION OPPORTUNITIES

Phase IV Product approval Phase III Phase II Phase I Pre-clinical Proof of concept



> Identification of biomarkers for the **development of diagnostic or prognostic tests for melanoma cancers** based on the correlation of biological and clinical data

- Clinical development

> Optimization of clinical studies (timing, measures and scales, sub population characterization, design...)

- > Support clinical enrollment
- > Epidemiological studies to identify the melanoma patients population in France
- > Epidemiological studies to support market access

— Outcomes research

> Pharmaco-epidemiological studies: drug safety, "real-world" use, effectiveness, practices patterns, acceptance, risk/benefit, risk management

- > Pharmaco-economic cost/benefit studies; Health economic outcomes
- > Comparative studies to assess product efficiency
- > Post-marketing studies

BIBLIOGRAPHY & COMMUNICATIONS

Congress and events

- > 45TH annual ESDR meeting (09/2015)
- > Journées dermatologiques de Paris (12/2014)
- > 10TH EADO Congress (05/2014)
- > 7^e Journées du Cancérolopôle Grand Ouest (04/2013)
- > 6º Forum Scientifique de Pharmaco-épidémiologie (06/2013)
- > 3º Journée Interrégionale du GIRCI Grand Ouest (06/2013)

Publications

> Review cases of discordant mutational statute

M. Saint-Jean *et al.*, **Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?** Journal of Investigative *Dermatology* (2014, vol.134, 1468-1470)

> Review cases of skin toxicities induced by vemurafenib:

L. Peuvrel *et al.*, **Profile of Vemurafenib-induced severe skin toxicities**, *Journal of the Europeau Academy of Dermatology and Venereology* [Epub ahead of print]

> Clinical data extractions for correlation with biological results:

A. Knol *et al.*, **Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline**, *Experimental Dermatology* [Submitted]